Investor mix
1 investor on record.
| Investor type | Count | Share |
|---|---|---|
| Private equity | 1 | 100% |
Specialty company developing anthracycline derivatives to eliminate cardiotoxicity side effect
1 investor on record.
| Investor type | Count | Share |
|---|---|---|
| Private equity | 1 | 100% |